HonorHealth

Intratumoral Immunotherapy—The Future of Treating Merkel Cell Carcinoma?

Merkel cell carcinoma (MCC) represents a rare but highly aggressive neuroendocrine skin cancer with limited systemic therapy options for patients who fail or are ineligible for immune checkpoint inhibitors (ICIs). Intratumoral (IT) immunotherapy has emerged as a promising strateg...

The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis

Background/Objectives: Biomarkers that can facilitate early detection of pancreatic cancer and extend patient survival are a significant unmet need. PancreaSure is a serum biomarker signature that performed well at distinguishing Stage I and II pancreatic ductal adenocarcinoma (P...

Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases

PURPOSE: Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has limited treatment options and responds poorly to conventional immunotherapy. We report extended follow-up results from a fully-enrolled, phase 1b cohort evaluating botensilimab (BOT; Fc-enhanced anti-CTLA-...

Risk Stratification of Patients Being Considered for Open Abdominal Aortic Aneurysm Repair

Background/Objectives: Endovascular repair (EVAR) is the default for most abdominal aortic aneurysms (AAAs), yet open repair (OR) remains necessary, and the decision hinges on fitness for open surgery. No standardized preoperative tool defines who is “unfit” for OR. We derived an...